These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21079194)

  • 21. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
    Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
    Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
    JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model.
    Terai K; Mizukami K; Okada M
    Nephrology (Carlton); 2008 Apr; 13(2):139-46. PubMed ID: 18275502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pathogenesis and treatment of vascular calcification in CKD].
    Brancaccio D; Gallieni M; Pasho S; Fallabrino G; Olivi L; Volpi E; Ciceri P; Missaglia E; Ronga C; Brambilla C; Butti A; Rocca-Rey L; Chiarelli G; Cozzolino M
    G Ital Nefrol; 2009; 26 Suppl 45():S20-7. PubMed ID: 19382090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium in chronic kidney disease: myths and realities. Introduction.
    Langman CB; Cannata-Andía JB
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S1-2. PubMed ID: 20089497
    [No Abstract]   [Full Text] [Related]  

  • 27. Gut microbiota; an overlooked effect of phosphate binders.
    Rahbar Saadat Y; Niknafs B; Hosseiniyan Khatibi SM; Ardalan M; Majdi H; Bahmanpoor Z; Abediazar S; Zununi Vahed S
    Eur J Pharmacol; 2020 Feb; 868():172892. PubMed ID: 31870830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.
    Sigrist MK; Chiarelli G; Lim L; Levin A
    J Ren Care; 2009 Mar; 35 Suppl 1():71-8. PubMed ID: 19222735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphate is a uremic toxin.
    Burke SK
    J Ren Nutr; 2008 Jan; 18(1):27-32. PubMed ID: 18089440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphate management-a dietitian's perspective.
    Kariyawasam D
    J Ren Care; 2009 Mar; 35 Suppl 1():79-83. PubMed ID: 19222736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
    Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ
    Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review.
    Rizk R; Hiligsmann M; Karavetian M; Evers SM
    Nephrology (Carlton); 2016 Mar; 21(3):178-87. PubMed ID: 26246269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB; Shepler BM
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphate binder choices used in ESRD patients.
    Nguyen T; Pham T; Huynh T
    Nephrol News Issues; 2016 Aug; 30(8):37-38. PubMed ID: 30513170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease].
    Cozzolino M; Butti A; Chiarelli G; Rocca-Rey L; Santagostino G; Gallieni M; Brancaccio D
    Ital Heart J Suppl; 2005 Jan; 6(1):25-8. PubMed ID: 15776728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
    Marangon N; Lindholm B; Stenvinkel P
    Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Phosphate binders].
    Heeb RM
    Med Monatsschr Pharm; 2016 Jun; 39(6):255-60. PubMed ID: 27439258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New developments in the management of hyperphosphatemia in chronic kidney disease.
    McIntyre CW
    Semin Dial; 2007; 20(4):337-41. PubMed ID: 17635825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.